Clindamycin

Generic Name: Clindamycin

Brand Names: Acanya, Benzaclin, Biacna, Cabtreo, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₃ClN_₂O_₅S

CAS Number: 18323-44-9

Unique Ingredient Identifier: 3U02EL437C

Background: Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.

Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.

Indication: In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci. Used topically, it is indicated for the treatment of acne vulgaris and is available in combination with benzoyl peroxide or tretinoin for this purpose, or as a triple combination therapy with benzoyl peroxide and adapalene. Clindamycin is also indicated as a vaginal cream, suppository, or gel for the treatment of bacterial vaginosis in non-pregnant females.

Clindamycin is used for antimicrobial prophylaxis against Viridans group streptococcal infections in susceptible patients undergoing oral, dental, or upper respiratory surgery, and may be used for prophylaxis against bacterial endocarditis in penicillin-allergic patients at high risk of these infections.

Associated Conditions: Abscess, Intra-Abdominal caused by Anaerobic Bacterial Infection, Acne Vulgaris, Babesiosis, Bacterial Endocarditis, Bacterial Vaginosis (BV), Bloodstream Infections caused by Anaerobic Bacterial Infection, Bone and Joint Infections caused by susceptible Staphylococcus, Empyema caused by Anaerobic Bacterial Infection, Endometritis caused by Anaerobic Bacterial Infection, Lung Abscess caused by Anaerobic Bacterial Infection, Malaria caused by Plasmodium falciparum, Mixed Vaginal Infections, Pelvic cellulitis caused by Anaerobic Bacterial Infection, Peritonitis caused by Anaerobic Bacterial Infection, Pneumocystis Jirovecii Pneumonia, Pneumonitis caused by Anaerobic Bacterial Infection, Respiratory Tract Infections (RTI) caused by susceptible Staphylococcus, Respiratory Tract Infections (RTI) caused by susceptible pneumococci, Respiratory Tract Infections (RTI) caused by susceptible streptococci, Septicemia caused by susceptible Staphylococcus, Septicemia caused by susceptible streptococci, Skin Structures and Soft Tissue Infections caused by Anaerobic Bacterial Infection, Skin Structures and Soft Tissue Infections caused by susceptible Staphylococcus, Skin Structures and Soft Tissue Infections caused by susceptible streptococci, Toxoplasmosis, Tubo-ovarian abscess caused by Anaerobic Bacterial Infection, Vaginal Candidiasis, Vaginal Mycosis, Chronic Bone and Joint Infections caused by Susceptible infections, Moderate Acne vulgaris, Post-surgical vaginal cuff infection caused by Anaerobic Bacterial Infection, Viridans group streptococci

Clinical Trials

Or v IV Antibiotics for Infection

Phase 3

Conditions: Joint Infection

Interventions: Drug: Bactrim
Drug: Cefadroxil
Drug: Doxycycline Hcl
Drug: Clindamycin

First Posted Date: 2021-01-26

Last Posted Date: 2021-01-26

Lead Sponsor: Rothman Institute Orthopaedics

Target Recruit Count: 308

Registration Number: NCT04723940

Locations: 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States

A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting

Phase 4

Completed

Conditions: Burn
Surgery
Infection Wound

Interventions: Drug: Cefazolin
Drug: Clindamycin

First Posted Date: 2020-08-18

Last Posted Date: 2022-08-26

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 32

Registration Number: NCT04516148

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

Phase 4

Active, not recruiting

Conditions: Bladder Carcinoma
Urinary Tract Infection
Refractory Bladder Carcinoma

Interventions: Drug: Clindamycin
Drug: Ertapenem
Other: Diary
Drug: Levofloxacin
Drug: Nitrofurantoin
Drug: Trimethoprim-Sulfamethoxazole

First Posted Date: 2020-08-06

Last Posted Date: 2024-07-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 89

Registration Number: NCT04502095

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Phase 2

Recruiting

Conditions: Skin Toxicity
Glioblastoma
Recurrent Glioblastoma

Interventions: Drug: Clindamycin Phosphate
Drug: Triamcinolone Acetonide

First Posted Date: 2020-07-13

Last Posted Date: 2024-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT04469075

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 5 locations